secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001828185-25-000058
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Q2 net loss $21.1M ($0.52/share); cash $87.8M, runway into 2027
-----------------------------------------------------------------------------

- Cash, cash equivalents & restricted cash $87.8M at June 30, 2025, down $12.8M from Q1.
- Q2 net loss $21.1M vs $19.7M in Q1; diluted EPS -$0.52 vs -$0.49.
- R&D expenses $8.0M in Q2, down from $8.3M Q1; VTP-1000 celiac trial lead driver.
- Phase 1 AVALON SAD final cohort ongoing; topline data expected early Q4 2025.
- MAD portion of AVALON started July 2025; data expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000058/0001828185-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000058/brns-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001828185-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer